LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.33 -3.62

Buy Sell

Overview

Share price change

24h

Current

Min

1.25

Max

1.37

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+177.54% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-1.2M 173M
Previous open	4.95
Previous close	1.33

News Sentiment

By Acuity

20%

80%

36 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 mar 2026, 19:32 UTC

Acquisitions, Mergers, Takeovers

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mar 2026, 22:26 UTC

Major News Events

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar 2026, 22:07 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar 2026, 21:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

6 mar 2026, 21:37 UTC

Earnings

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar 2026, 21:25 UTC

Major News Events

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar 2026, 21:17 UTC

Earnings

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar 2026, 20:50 UTC

Earnings

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar 2026, 20:46 UTC

Earnings

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar 2026, 20:31 UTC

Major News Events

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar 2026, 20:12 UTC

Market Talk

Major News Events

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar 2026, 19:10 UTC

Market Talk

Major News Events

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar 2026, 18:44 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar 2026, 18:08 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mar 2026, 17:46 UTC

Major News Events

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mar 2026, 17:40 UTC

Market Talk

Earnings

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mar 2026, 17:40 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 17:32 UTC

Market Talk

Major News Events

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mar 2026, 17:28 UTC

Market Talk

Major News Events

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mar 2026, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

6 mar 2026, 17:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

6 mar 2026, 17:20 UTC

Acquisitions, Mergers, Takeovers

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

177.54% upside

12 Months Forecast

Average 3.83 USD 177.54%

High 7 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

36 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.